Variant Pharmaceuticals Has a New Name - ZyVersa Therapeutics, Inc.
Co-Founder, Chief Executive Officer, and President
Mr. Glover has over 32 years of business experience in biopharmaceuticals and life sciences. Mr. Glover is formally the Co-Founder of Coherus Biosciences where he was focused on the business strategy, partnerships, product development efforts and capitalization of the company. Prior to Coherus, he was the President of Insmed Therapeutic Proteins as well as Chief Business Officer of Insmed Incorporated. At Insmed, Mr. Glover was responsible for the creation of the biosimilar business unit and the divestiture of the business to Merck. As Chief Business Officer he led Insmed's strategic review process which resulted in the merger of Insmed and Transave. Prior to Insmed, Mr. Glover held the position of Senior Vice President and General Manager at Andrx Laboratories and Andrx Therapeutics, both divisions of Andrx Corporation. At Andrx Mr. Glover was responsible for the strategy and operation of the Andrx Labs which developed and marketed products in metabolic diseases and Men's Health, and Andrx Therapeutics which was focused on the development of new controlled release products and contract manufacturing. He earlier held multiple sales, marketing and operational roles at Hoffman LaRoche, Amgen Inc. and IMS Health. Mr. Glover has multifaceted experience in Fortune 100, start up and entrepreneurial environments. His transaction experience covers over 25 transactions totaling over $10 billion, and he serves on the Boards of PDS Biotechnology, INCON, and Asclepius Lifesciences.
Chairman of the Board
Former CEO & President of Janssen (Johnson & Johnson) companies and Ares-Serono, Inc.
In the course of his career in the Pharmaceutical and Biotechnology Industry, mainly at Johnson & Johnson [NYSE: JNJ], Jules A. Müsing has been responsible for the worldwide licensing and acquisition of pharmaceutical and biotechnology prescription products and technologies and the establishment of corporate strategic alliances.
In this position he negotiated, signed and implemented several multi-million dollar deals with small, medium and large Pharmaceutical and Biotechnology companies on a worldwide basis.
He has more than 40 years' experience in the pharmaceutical and biotechnology industry, and has been Chief Executive Officer, President and Managing Director of Johnson & Johnson companies in the US and in Europe and of the Swiss-based company Ares Serono in the US. He also has been Executive Vice President of all Ares Serono companies in North- and Latin America.
Additional accomplishments relate to his business development activities in S.E. Asia, where he was instrumental in the establishment of Johnson & Johnson pharmaceutical subsidiaries in Japan, Australia, South Africa, Thailand and other S.E. Asian countries, and to his role of Vice President Marketing International for the Janssen Group of Companies Worldwide.
Mr. Müsing currently serves as a member of the Board of Directors of TherapeuticsMD, Inc. and of Delphi Digital, Inc. He is also Chairman of the Scientific Advisory Board of Noble Capital Markets, an Investment Banking and Merchant Banking boutique in Boca Raton, Florida.
Mr. Müsing previously served as a member of the Board of Directors of Johnson & Johnson companies in Germany, France, Italy and the UK and served as a member of the Management Board of Ortho Biotech, a Johnson & Johnson biotechnology company in the US and in Europe. He also served as Executive Chairman of Pelican Therapeutics, Inc. and as a member of the Board of Directors of iBio, Inc.
Jules A. Müsing received his Postgraduate degree of Master in Sciences from the University of Brussels (Belgium) and his Academic degree in Economic and Financial Sciences - Cum Lauda - from the University of Antwerp (Belgium). He also completed several Postgraduate courses at Harvard University, US and the University of Cambridge, UK. His Honors thesis on the European Monetary Union (1975) was awarded with "special recognition" by the Prime Minister of Belgium.
He has been speaker and moderator at several national and international Healthcare conferences and congresses, and is an advisor to a number of Biotechnology and Pharmaceutical companies.
Chief Executive Officer, Co-Founder, and Director of TherapeuticsMD Inc.
Mr. Finizio is Chief Executive Officer, Co-Founder, and Director of TherapeuticsMD Inc., an innovative women's health pharmaceutical company. With over 20 years of healthcare experience, Rob started his career in an operational role at Endoscopy Specialist, Inc. (ESI), a leader in laparoscopic equipment outsourcing and intraoperative technical support. During his tenure at ESI, Rob advanced to a regional management role, eventually leaving to join Omnicell Technologies (OMCL), a leader in pharmacy automation.
While at Omnicell, Rob served as a sales director, ultimately leaving the company to co-found CareFusion in 2001. CareFusion was a pioneer in hospital patient safety systems for Medication, Blood, and Specimen verification at the point of care. The company was successfully sold to Cardinal Health in 2006.
Rob co-founded TherapeuticsMD (TXMD) in 2008, combining his background in women's healthcare, pharmaceutical technology, clinical software, and patient safety. Today, TXMD is a leader in women's health, pharmaceutical development, and commercialization. In 2011, Rob took TXMD public, with a current market capitalization of over a billion dollars. Since inception, Rob raised more than $500 million in capital and listed TXMD on the NYSE before transferring to the Nasdaq in 2017.
Rob sits on the Board of Directors for two non-profit organizations, BioFlorida and the Boca Raton Police Foundation. Prior to his healthcare career, Rob, a University of Miami graduate who earned a Bachelor of Arts degree majoring in Premed and Psychology, taught English in Osaka, Japan.
Former President and CEO of Cynapsus Therapeutics
Executive Chairman of Sublimity Therapeutics
Mr. Giovinazzo has in excess of 38 years of professional experience. His first seven years were spent as an international corporate tax specialist primarily in multinational conglomerates. The subsequent eight years were spent in Fortune 100 investment banking and private equity. For the last 24 years he has solely been focused in the discovery, development and commercialization of therapeutics for Alzheimer's, Parkinson's and neuropathic pain.
In September 2017, he was honored as the first Bloom Burton Award recipient, having been chosen as the best of the best in Canada by a panel of leading US biopharmaceutical experts.
Mr. Giovinazzo, who is currently retired, is an executive chairman of Sublimity Therapeutics Ltd, a private Irish-American company that recently raised US $64 million from three leading international private equity funds. He is also a Director on the Board of Promis Neurosciences Inc. From October 2016 to March 2017, he was the President and CEO of Sunovion CNS Development Canada ULC, a successor company to Cynapsus Therapeutics Inc., which was purchased in the fall of 2016 by Sunovion Pharmaceuticals Inc. He was President, CEO and a Director of Cynapsus Therapeutics Inc. from 2009 to 2016. During this period, he led the company in raising $136 million in private and public equity. He was one of the three original inventors and patent holders of the Cynapsus Parkinson's focused technology. The sale of Cynapsus resulted in a 120% premium to market price, a Canadian $841 million all cash M&A transaction.
Mr. Giovinazzo is the co-author of several peer reviewed papers and author of several papers on strategic and financing issues in the biopharmaceutical industry. During his career he was involved in several licensing and M&A transactions. In addition, he has raised in excess of US $750 million in private and public equity. He was a finalist in the E&Y Entrepreneur of the Year (2014) for Ontario Canada. He is a Chartered Director and is Audit Committee Certified, both from The Directors College, a degree granting affiliate of McMaster University, Hamilton Canada. He completed the Leadership and Strategy in Pharmaceuticals and Biotech program in 2006 from Harvard Business School, and received a Master's of Business Administration from IMD, Geneva Switzerland in 1986, Mr. Giovinazzo completed a Graduate Certificate Studies in Canadian Law from Osgoode Hall Law School York University, Toronto, Ontario (1984), and his Bachelor of Arts in Economics and Accounting at McMaster University (1978).
Chief Executive Officer, G&W Laboratories, Inc.
Mr. Greenblatt has been the Chief Executive Officer of G&W Laboratories, Inc. since March 12, 2015. Mr. Greenblatt previously served as Chief Commercial Officer and Executive Vice President at G&W Laboratories, Inc. Mr. Greenblatt rotated through several departments in G&W during various summer internships throughout high school and college and joined G&W full-time in 2009 as the head of Supply Chain. After building the newly formed Supply Chain department at G&W, Mr. Greenblatt also ran the packaging department before becoming Director of Sales, Business Development, and Company Culture. Then, as Chief Commercial Officer, Mr. Greenblatt was the architect and chief negotiator of G&W’s first and second acquisitions, tripling its manufacturing footprint and employee base in a twelve month period. Mr. Greenblatt also focused on deepening customer relationships and ensuring that G&W attracts and retains employees who are aligned with its core values.
As the fourth generation CEO from the Greenblatt family, Mr. Greenblatt continues to focus on instilling the core values into the company culture, talent-recruitment and development, commercial partnerships, and new product acquisitions, in order to further increase the company’s growth trajectory, and continue to build a sustainable organization.
Founder and CEO, Riverstone Investment Co., Ltd.
Chairman, INCON and NDFOS
Mr. Kim has more than 15 years of professional experience managing private equity funds. During his career, he has executed up to $400 million in M&A transactions.
Mr. Kim is founder & CEO of Riverstone Investment Co., Ltd., which was formed in 2010, and Chairman of INCON (KOSDAQ:083640) and NDFOS (KOSDAQ:238090).
Mr. Kim was formerly Co-founder & CIO at Liberty Investment Co., Ltd. He received a BA in economics from Cornell University.
Former President & CEO of PharmAthene; Chairman of LabConnect
Mr. Richman has more than 25 years of experience as a life science executive and has been instrumental in the growth and success of a number of life science companies. As a member of the founding team of MedImmune, his responsibilities included the commercial launches of rare disease and oncology products, and he served in various roles in strategic planning, business development and international operations.
From 2007 through 2015, Mr. Richman was President & CEO of PharmAthene, Inc. He is a former Venture Partner at Brace Pharma Capital.
Mr. Richman is Chairman of LabConnect and serves on the Boards of ADMA Biologics (NASDAQ: ADMA), and NovelStem International, Corp. Former Board roles include PharmAthene, Inc., LEV Pharmaceuticals, Tyrogenex, Inc., Siga Technologies, and American Bank.